OUTCOME OF PATIENTS WITH NONSECRETORY AND SECRETORY MULTIPLE MYELOMA AFTER FIRST LINE TREATMENT CONSOLIDATED WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION. THE SINGLE CENTRE EXPERIENCE
(Abstract release date: 05/19/16)
EHA Library. Romejko-Jarosinska J. 06/09/16; 134888; PB1988
Dr. Joanna Romejko-Jarosinska
Contributions
Contributions
Abstract
Abstract: PB1988
Type: Publication Only
Background
Nonsecretory multiple myeloma (NSM) is an uncommon type of multiple myeloma. It is defined as the presence of monoclonal plasma cells in bone marrow biopsy or in other organs and the absence of monoclonal protein in immunofixation in serum and urine. There are limited data about outcome after first line treatment with consolidation high dose chemotherapy following autologous hematopoietic stem cell transplantation (ASCT).
Aims
We retrospectively evaluated outcomes and predictive factors for overall survival (OS) and progression free survival (PFS) in all myeloma patients, in non-secretory myeloma (NSM) and in secretory myeloma (SM) groups, who received high dose chemotherapy and ASCT between 1998 – 2015 after first line treatment.
Methods
We identified 114 myeloma patients: 23 (20%) with non-secretory myeloma and 91 (80%) with secretory myeloma. Median time from first treatment to ASCT was 8 months (range 4–28 months). All patients achieved response to first line treatment: complete remission or partial response.
Results
The median OS and median PFS were 41 (range 2- 205) months and 25 (range: 2- 205) months, respectively. Five year OS and 5-year PFS were 70% [95%CI (59%, 79%)] and 42% [95%CI(31%, 53%)], respectively. For NSM and SM groups 5-year OS were 54%[95%CI (31%,77%) and 74%[95%CI(64%,75%)] respectively, (p=0.14) and 5-year PFS were 45%[95%CI(24%,66%)] and 41%[95%CI (29%,53%), respectively. (p=0.79). Age, sex, disease stage, disease status before ASCT, induction chemotherapy, radiotherapy had no influence on OS and PFS for all, NSM and SM groups in univariant analysis. The presence of monoclonal IgG protein in SM patients was associated with better OS compared to OS in NSM group (p=0.04) and the presence of monoclonal protein with kappa light chain in SM patients related to longer PFS compared to PFS in NSM group (p=0.05) in univariant analysis.
Conclusion
There were no significant differences in OS and PFS for non secretory and secretory myeloma patients after first line treatment consolidated by high dose chemotherapy and ASCT. However, patients with monoclonal IgG protein had significantly better OS than patients with NSM.
Session topic: E-poster
Keyword(s): Autologous bone marrow transplant, Monoclonal gammopathy, Myeloma
Type: Publication Only
Background
Nonsecretory multiple myeloma (NSM) is an uncommon type of multiple myeloma. It is defined as the presence of monoclonal plasma cells in bone marrow biopsy or in other organs and the absence of monoclonal protein in immunofixation in serum and urine. There are limited data about outcome after first line treatment with consolidation high dose chemotherapy following autologous hematopoietic stem cell transplantation (ASCT).
Aims
We retrospectively evaluated outcomes and predictive factors for overall survival (OS) and progression free survival (PFS) in all myeloma patients, in non-secretory myeloma (NSM) and in secretory myeloma (SM) groups, who received high dose chemotherapy and ASCT between 1998 – 2015 after first line treatment.
Methods
We identified 114 myeloma patients: 23 (20%) with non-secretory myeloma and 91 (80%) with secretory myeloma. Median time from first treatment to ASCT was 8 months (range 4–28 months). All patients achieved response to first line treatment: complete remission or partial response.
Results
The median OS and median PFS were 41 (range 2- 205) months and 25 (range: 2- 205) months, respectively. Five year OS and 5-year PFS were 70% [95%CI (59%, 79%)] and 42% [95%CI(31%, 53%)], respectively. For NSM and SM groups 5-year OS were 54%[95%CI (31%,77%) and 74%[95%CI(64%,75%)] respectively, (p=0.14) and 5-year PFS were 45%[95%CI(24%,66%)] and 41%[95%CI (29%,53%), respectively. (p=0.79). Age, sex, disease stage, disease status before ASCT, induction chemotherapy, radiotherapy had no influence on OS and PFS for all, NSM and SM groups in univariant analysis. The presence of monoclonal IgG protein in SM patients was associated with better OS compared to OS in NSM group (p=0.04) and the presence of monoclonal protein with kappa light chain in SM patients related to longer PFS compared to PFS in NSM group (p=0.05) in univariant analysis.
Conclusion
There were no significant differences in OS and PFS for non secretory and secretory myeloma patients after first line treatment consolidated by high dose chemotherapy and ASCT. However, patients with monoclonal IgG protein had significantly better OS than patients with NSM.
Session topic: E-poster
Keyword(s): Autologous bone marrow transplant, Monoclonal gammopathy, Myeloma
Abstract: PB1988
Type: Publication Only
Background
Nonsecretory multiple myeloma (NSM) is an uncommon type of multiple myeloma. It is defined as the presence of monoclonal plasma cells in bone marrow biopsy or in other organs and the absence of monoclonal protein in immunofixation in serum and urine. There are limited data about outcome after first line treatment with consolidation high dose chemotherapy following autologous hematopoietic stem cell transplantation (ASCT).
Aims
We retrospectively evaluated outcomes and predictive factors for overall survival (OS) and progression free survival (PFS) in all myeloma patients, in non-secretory myeloma (NSM) and in secretory myeloma (SM) groups, who received high dose chemotherapy and ASCT between 1998 – 2015 after first line treatment.
Methods
We identified 114 myeloma patients: 23 (20%) with non-secretory myeloma and 91 (80%) with secretory myeloma. Median time from first treatment to ASCT was 8 months (range 4–28 months). All patients achieved response to first line treatment: complete remission or partial response.
Results
The median OS and median PFS were 41 (range 2- 205) months and 25 (range: 2- 205) months, respectively. Five year OS and 5-year PFS were 70% [95%CI (59%, 79%)] and 42% [95%CI(31%, 53%)], respectively. For NSM and SM groups 5-year OS were 54%[95%CI (31%,77%) and 74%[95%CI(64%,75%)] respectively, (p=0.14) and 5-year PFS were 45%[95%CI(24%,66%)] and 41%[95%CI (29%,53%), respectively. (p=0.79). Age, sex, disease stage, disease status before ASCT, induction chemotherapy, radiotherapy had no influence on OS and PFS for all, NSM and SM groups in univariant analysis. The presence of monoclonal IgG protein in SM patients was associated with better OS compared to OS in NSM group (p=0.04) and the presence of monoclonal protein with kappa light chain in SM patients related to longer PFS compared to PFS in NSM group (p=0.05) in univariant analysis.
Conclusion
There were no significant differences in OS and PFS for non secretory and secretory myeloma patients after first line treatment consolidated by high dose chemotherapy and ASCT. However, patients with monoclonal IgG protein had significantly better OS than patients with NSM.
Session topic: E-poster
Keyword(s): Autologous bone marrow transplant, Monoclonal gammopathy, Myeloma
Type: Publication Only
Background
Nonsecretory multiple myeloma (NSM) is an uncommon type of multiple myeloma. It is defined as the presence of monoclonal plasma cells in bone marrow biopsy or in other organs and the absence of monoclonal protein in immunofixation in serum and urine. There are limited data about outcome after first line treatment with consolidation high dose chemotherapy following autologous hematopoietic stem cell transplantation (ASCT).
Aims
We retrospectively evaluated outcomes and predictive factors for overall survival (OS) and progression free survival (PFS) in all myeloma patients, in non-secretory myeloma (NSM) and in secretory myeloma (SM) groups, who received high dose chemotherapy and ASCT between 1998 – 2015 after first line treatment.
Methods
We identified 114 myeloma patients: 23 (20%) with non-secretory myeloma and 91 (80%) with secretory myeloma. Median time from first treatment to ASCT was 8 months (range 4–28 months). All patients achieved response to first line treatment: complete remission or partial response.
Results
The median OS and median PFS were 41 (range 2- 205) months and 25 (range: 2- 205) months, respectively. Five year OS and 5-year PFS were 70% [95%CI (59%, 79%)] and 42% [95%CI(31%, 53%)], respectively. For NSM and SM groups 5-year OS were 54%[95%CI (31%,77%) and 74%[95%CI(64%,75%)] respectively, (p=0.14) and 5-year PFS were 45%[95%CI(24%,66%)] and 41%[95%CI (29%,53%), respectively. (p=0.79). Age, sex, disease stage, disease status before ASCT, induction chemotherapy, radiotherapy had no influence on OS and PFS for all, NSM and SM groups in univariant analysis. The presence of monoclonal IgG protein in SM patients was associated with better OS compared to OS in NSM group (p=0.04) and the presence of monoclonal protein with kappa light chain in SM patients related to longer PFS compared to PFS in NSM group (p=0.05) in univariant analysis.
Conclusion
There were no significant differences in OS and PFS for non secretory and secretory myeloma patients after first line treatment consolidated by high dose chemotherapy and ASCT. However, patients with monoclonal IgG protein had significantly better OS than patients with NSM.
Session topic: E-poster
Keyword(s): Autologous bone marrow transplant, Monoclonal gammopathy, Myeloma
{{ help_message }}
{{filter}}